Wingstop (WING) Q2 2025 Earnings Report Highlights Revenue Growth and Strategic Partnerships
Wingstop (WING) reported Q2 2025 earnings with net revenue of $12.5 million, up 45% year-over-year and 44% sequentially, driven by commercial growth in PKD and higher units processed through specialty pharmacy. The company also announced strategic revenue-sharing agreements with Avanzanite Bioscience and NewBridge Pharmaceuticals for PYRUKYND commercialization.

Topics: cash position earnings report R&D expenses revenue growth strategic partnerships